Publications by authors named "Anne Rodallec"

Claim this Profile
P
Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models.
Mathilde Dacos, Benoît Immordino, Erwan Diroff, Guillaume Sicard, Artemis Kosta, Anne Rodallec

Int J Pharm· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors.
Patricia Piris, Duje Buric, Toshihide Yamasaki, Paul Huchedé, Maïlys Rossi, Anne Rodallec

Chem Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic.
Anne Rodallec, Cristina Vaghi, Joseph Ciccolini, Raphaelle Fanciullino, Sebastien Benzekry

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Elise Timon-David, Carla Perez, Anne Rodallec

Pharmaceutics· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer.
Guillaume Sicard, Clément Paris, Sarah Giacometti, Anne Rodallec, Joseph Ciccolini

Pharmaceutics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Anne Rodallec, Guillaume Sicard, Sarah Giacometti, Manon Carre, Thomas Maia

Anticancer Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors.
Cristina Vaghi, Anne Rodallec, Raphaëlle Fanciullino, Joseph Ciccolini, Jonathan P Mochel

PLoS Comput Biol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.
Anne Rodallec, Raphaelle Fanciullino, Sebastien Benzekry, Joseph Ciccolini,

Anticancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
Anne Rodallec, Guillaume Sicard, Sarah Giacometti, Manon Carré, Bertrand Pourroy

Int J Nanomedicine· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles.
Anne Rodallec, Guillaume Sicard, Raphaelle Fanciullino, Sébastien Benzekry, Bruno Lacarelle

Expert Opin Drug Metab Toxicol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.
Anne Rodallec, Sebastien Benzekry, Bruno Lacarelle, Joseph Ciccolini, Raphaelle Fanciullino

Crit Rev Oncol Hematol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
Anne Rodallec, Jean-Michel Brunel, Sarah Giacometti, Helene Maccario, Florian Correard

Int J Nanomedicine· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.
Anne Rodallec, Raphaelle Fanciullino, Bruno Lacarelle, Joseph Ciccolini

Expert Rev Clin Pharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Claramines: A New Class Of Broad-Spectrum Antimicrobial Agents With Bimodal Activity.
Marine Blanchet, Diane Borselli, Anne Rodallec, Franck Peiretti, Nicolas Vidal

ChemMedChem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
Jérémie Guedj, Géraldine Piorkowski, Frédéric Jacquot, Vincent Madelain, Thi Huyen Tram Nguyen, Anne Rodallec

PLoS Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
Thi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, Cédric Laouénan, Vincent Madelain, Anne Rodallec

PLoS Negl Trop Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
Manon Launay, Laetitia Dahan, Manon Duval, Anne Rodallec, Gérard Milano

Br J Clin Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis